Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Of monkeys and men: analysis of the phase 2 double-blind, sham-surgery controlled, randomized trial of AAV2-neurturin gene therapy for Parkinson's disease.

Literature DB >> 21505812

Of monkeys and men: analysis of the phase 2 double-blind, sham-surgery controlled, randomized trial of AAV2-neurturin gene therapy for Parkinson's disease.

Daniel E Huddleston¹, Stewart A Factor.

Abstract

Entities: Disease Species

Year: 2011 PMID： 21505812 DOI： 10.1007/s11910-011-0206-y

Source DB: PubMed Journal: Curr Neurol Neurosci Rep ISSN： 1528-4042 Impact factor: 5.081

× No keyword cloud information.

10 in total

Review 1. Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself?

Authors: Jeffrey H Kordower; C Warren Olanow
Journal: Exp Neurol Date: 2007-08-22 Impact factor: 5.330

Review 2. Design of clinical trials of gene therapy in Parkinson disease.

Authors: Travis B Lewis; David G Standaert
Journal: Exp Neurol Date: 2007-08-31 Impact factor: 5.330

3. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

Authors: Jeffrey H Kordower; Christopher D Herzog; Biplob Dass; Roy A E Bakay; James Stansell; Mehdi Gasmi; Raymond T Bartus
Journal: Ann Neurol Date: 2006-12 Impact factor: 10.422

4. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

Authors: Peter A LeWitt; Ali R Rezai; Maureen A Leehey; Steven G Ojemann; Alice W Flaherty; Emad N Eskandar; Sandra K Kostyk; Karen Thomas; Atom Sarkar; Mustafa S Siddiqui; Stephen B Tatter; Jason M Schwalb; Kathleen L Poston; Jaimie M Henderson; Roger M Kurlan; Irene H Richard; Lori Van Meter; Christine V Sapan; Matthew J During; Michael G Kaplitt; Andrew Feigin
Journal: Lancet Neurol Date: 2011-04 Impact factor: 44.182

5. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.

Authors: Raymond T Bartus; Christopher D Herzog; Yaping Chu; Alistair Wilson; Lamar Brown; Joao Siffert; Eugene M Johnson; C Warren Olanow; Elliott J Mufson; Jeffrey H Kordower
Journal: Mov Disord Date: 2010-11-18 Impact factor: 10.338

6. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease.

Authors: Mehdi Gasmi; Christopher D Herzog; Eugene P Brandon; Justine J Cunningham; G Anthony Ramirez; Elias T Ketchum; Raymond T Bartus
Journal: Mol Ther Date: 2007-01 Impact factor: 11.454

7. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.

Authors: Christopher D Herzog; Biplob Dass; James E Holden; James Stansell; Mehdi Gasmi; Mark H Tuszynski; Raymond T Bartus; Jeffrey H Kordower
Journal: Mov Disord Date: 2007-06-15 Impact factor: 10.338

8. Functional recovery in parkinsonian monkeys treated with GDNF.

Authors: D M Gash; Z Zhang; A Ovadia; W A Cass; A Yi; L Simmerman; D Russell; D Martin; P A Lapchak; F Collins; B J Hoffer; G A Gerhardt
Journal: Nature Date: 1996-03-21 Impact factor: 49.962

Review 9. Norepinephrine: The redheaded stepchild of Parkinson's disease.

Authors: K S Rommelfanger; D Weinshenker
Journal: Biochem Pharmacol Date: 2007-02-03 Impact factor: 5.858

10. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.

Authors: Anthony E Lang; Steven Gill; Nik K Patel; Andres Lozano; John G Nutt; Richard Penn; David J Brooks; Gary Hotton; Elena Moro; Peter Heywood; Matthew A Brodsky; Kim Burchiel; Patrick Kelly; Arif Dalvi; Burton Scott; Mark Stacy; Dennis Turner; V G Frederich Wooten; William J Elias; Edward R Laws; Vijay Dhawan; A Jon Stoessl; James Matcham; Robert J Coffey; Michael Traub
Journal: Ann Neurol Date: 2006-03 Impact factor: 10.422